Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “interleukin-”

120 pharma patents match "interleukin-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 120
Index total 30,257
Page 1 / 5

Quick answer

This filtered view shows 120 pharmaceutical patents matching "interleukin-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

120 results for “interleukin-” · 30,257 patents in full index Clear search

  1. US 12359204

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  2. US 12291571

    Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody

    REGENERON PHARMACEUTICALS, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  3. US 12280108

    Vaccines having an antigen and interleukin-21 as an adjuvant

    Inovio Pharmaceuticals, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  4. US 12247206

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  5. US 12201673

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  6. US 12157762

    Tethered interleukin-15 and interleukin-21

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  7. US 12077593

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  8. US 12036283

    Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

    Nektar Therapeutics · Granted Jul 16, 2024 · Expires Jul 11, 2044

    granted
  9. US 12018057

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  10. US 11981739

    Chimeric antigen receptor specific for interleukin-23 receptor

    SANGAMO THERAPEUTICS FRANCE · Granted May 14, 2024 · Expires May 9, 2044

    granted
  11. US 11981716

    Activatable interleukin-2 polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. · Granted May 14, 2024 · Expires May 9, 2044

    granted
  12. US 11944666

    Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 2, 2024 · Expires Mar 28, 2044

    granted
  13. US 11939361

    Compositions of peptide inhibitors of Interleukin-23 receptor

    Protagonist Therapeutics, Inc. · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  14. US 11926670

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  15. US 11897874

    Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

    Corvus Pharmaceuticals, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  16. US 11884748

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  17. US 11866503

    Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  18. US 11844765

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  19. US 11845808

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  20. US 11807853

    Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  21. US 11718655

    Masked interleukin-12 polypeptides

    Xilio Development, Inc. · Granted Aug 8, 2023 · Expires Aug 3, 2043

    granted
  22. US 11701384

    Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments

    The Regents of the University of California · Granted Jul 18, 2023 · Expires Jul 13, 2043

    granted
  23. US 11680090

    Interleukin-2 fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Jun 20, 2023 · Expires Jun 15, 2043

    granted
  24. US 11535658

    Activatable interleukin-2 polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. · Granted Dec 27, 2022 · Expires Dec 22, 2042

    granted